AUMED a.s. focuses on the research and development of bacteriophage-based preparations, targeting the skin pathogens present in acne vulgaris. This condition is characterized by an overgrowth of the bacterium Cutibacterium acnes as well as Staphylococcus aureus, which contribute to local inflammatory manifestations. The use of a bacteriophage preparation decolonizes the skin from the mentioned bacteria and thus allows it to regenerate.
Acne is currently treated with preparations based on retinoids, antibiotics, or hydroxy acids. With each of these approaches, there are more or less serious side effects, including skin erythema. Due to the sensitivity of the skin suffering from acne, it is necessary to choose methods that are gentler on the skin and the whole organism. Bacteriophages are free of any side effects and work very quickly compared to other methods. Compared to antibiotics, they are also gentle on the remaining skin microflora and only target S. aureus and C. acnes.
The result of this work is a preparation containing bacteriophages, which effectively decolonizes acne-prone skin from S. aureus and C. acnes bacteria.
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
